Delivery of novel coumarin–dihydropyrimidinone conjugates through mixed polymeric nanoparticles to potentiate therapeutic efficacy against triple-negative breast cancer

Ghosh, Avijit; Upadhyay, Priyanka; Sarker, Sushmita; Das, Shaswati; Bhattacharjee, Mousumi; Bhattacharya, Saurav; Ahir, Manisha; Guria, Subhajit; Gupta, P. C. Sen; Chattopadhyay, Sreya; Ghosh, Swatilekha; Adhikari, Susanta; Adhikary, Arghya

doi:10.1039/d1bm00424g

Cited by 4 publications

(1 citation statement)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The advantage of using PEGNPs is that the carriers keep the drugs and additional biologically active fragments protected from the environment and increase the bioavailability and therapeutic index of the drugs [8,9]. It was reported that a coumarin-dihydropyrimidinone formulated in poly(lactic-co-glycolic acid) (PLGA)-PEG 4000 mixed copolymer nanoparticles showed excellent therapeutic effect on a wide variability of cancer cell lines [10].…”

Section: Introductionmentioning

confidence: 99%

PEG-4000 formed polymeric nanoparticles loaded with cetuximab downregulate p21 & stathmin-1 gene expression in cancer cell lines

et al. 2022

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

PEG-4000 formed polymeric nanoparticles loaded with cetuximab downregulate p21 & stathmin-1 gene expression in cancer cell lines

et al. 2022

View full text Add to dashboard Cite

Nanocarrier mediated co-delivery of phytochemicals and chemo-drugs: an emerging strategy to combat lung cancer in a systemic way

Upadhyay,

Ghosh,

Sarangthem

et al. 2023

Phytochem Rev

View full text Add to dashboard Cite

Nanomedicine mediated thyroid cancer diagnosis and treatment: an approach from generalized to personalized medicine

Gulwani,

Upadhyay,

Goel

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Thyroid cancer (TC) being the common endocrine malignancy is glooming steadily due to its poor prognosis. The treatment strategies of surgery, radiotherapy, and conventional chemotherapy are providing unsatisfactory output. However, combination therapy can negotiate the worse prognosis to the better, where chemoradiotherapy, radiotherapy with surgery, or dual chemotherapeutic drugs are being glorified. Chemotherapy includes the use of doxorubicin or taxanes generally with platinum-based drugs viz. cisplatin or carboplatin that are administered alone or along with multitarget tyrosine kinase inhibitors viz. Lenvatinib, Sorafenib, Sunitinib, Vandetanib, Pyrazolo-pyrimidine compounds, etc., single target tyrosine kinase inhibitors like Dabrafenib plus Trametinib and Vemurafenib against BRAF, Gefitinib against EGFR, Everolimus against mTOR, vascular disruptors like Fosbretabulin, and immunotherapy with viz. Spartalizumab and Pembrolizumab, are anti-PD-1/PD-L1 molecules. Hence, several trials are currently evaluating the possible beneficial role of combinatorial therapy in TC. Since TC is the outcome of multiple genetic alterations, it necessitates targeting the multiple factors in a single shot. These combination strategies for systemically delivering therapeutic drugs seem feasible only with the help of theranostic. To date, nanoparticle-based drug delivery systems (NDDS) have devoted themselves to diagnosis, bioimaging, imaging-assisted surgery, and therapy with high success rates. The ease of handling hybrid technologies is also selectively admirable. However, in this review, we have summarized the sequential progression of chemotherapeutic drugs to NDDS designed for Personalized Medicine (PM) against TC. Personalized medicine is an ever-growing field that will be explored in future discoveries in biomedicine, particularly cancer theranostics. Hence, our review presents a closer view of NDDS as a personalized treatment for TC. We have also discussed the primary challenges facing NDDS in meeting excellence in PM.

show abstract

Delivery of novel coumarin–dihydropyrimidinone conjugates through mixed polymeric nanoparticles to potentiate therapeutic efficacy against triple-negative breast cancer

Abstract: Till date most of the accessible therapeutic options are virtually non-responsive towards Triple-negative breast cancer (TNBC) due to their highly aggressive and metastatic nature. Interestingly, chemotherapy reacts soundly in many...

Cited by 4 publications

References 69 publications

PEG-4000 formed polymeric nanoparticles loaded with cetuximab downregulate p21 & stathmin-1 gene expression in cancer cell lines

PEG-4000 formed polymeric nanoparticles loaded with cetuximab downregulate p21 & stathmin-1 gene expression in cancer cell lines

Nanocarrier mediated co-delivery of phytochemicals and chemo-drugs: an emerging strategy to combat lung cancer in a systemic way

Nanomedicine mediated thyroid cancer diagnosis and treatment: an approach from generalized to personalized medicine

Contact Info

Product

Resources

About